Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Characteristics of expedited programmes for cancer drug approval in China

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 20, 416 (2021)



The authors gratefully acknowledge Yi-Long Wu (Guangdong Lung Cancer Institute) and Yale Jiang (Tsinghua University) for contributing to this manuscript. We also thank Wei Xie and Yunhe Qin (Pharmcube) for data processing.

Supplementary Information

  1. Supplementary information

Competing Interests

C.X. is an employee at Pharmcube. The other authors declare no competing interests.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links